Whole-body MRI scans to predict outcomes in multiple myeloma after stem cell transplant
Examines MRI scan findings after stem cell transplant in newly diagnosed multiple myeloma.
Plain-language title generated from the registry record
Registry title: Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
Key facts
- Where
- Bari, Bologna, Brescia, Castelfranco Veneto, Como, Milan, Novara, Pavia, and Rome, ItalySee the 10 sites
Where in Italy
- IRCCS Istituto Tumori "G. Paolo II - U.O.C. Ematologia e Terapia CellulareBari, ItalyNo longer taking part
- A.O.U. di Bologna Policlinico S.Orsola MalpighiBologna, ItalyNo longer taking part
- A.O. Spedali Civili di BresciaBrescia, ItalyNo longer taking part
- Istituto Oncologico Veneto IRCCS - UOC OncoematologiaCastelfranco Veneto, ItalyNo longer taking part
- Ospedale Classificato ValduceComo, ItalyNo longer taking part
- I.R.C.C.S. Ospedale S. RaffaeleMilan, ItalyNo longer taking part
- Ospedale NiguardaMilan, ItalyNo longer taking part
- A.O.U. Maggiore della CaritàNovara, ItalyNo longer taking part
- Policlinico S. Matteo Fondazione IRCCSPavia, ItalyNo longer taking part
- ASL Roma 1Rome, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione EMN Italy Onlus
- Trial code
- NCT07746232
- Record updated
- 9 September 2026
- Original description
This is a multicenter, observational, retrospective-prospective study designed to validate the predictive role of advanced imaging in patients with newly diagnosed multiple myeloma (NDMM). The main purpose of this study is to estimate the prevalence of radiological response categories (Response Assessment Category, RAC score) and evaluate the predictive value of relative Fat Fraction (rFF%) using Diffusion-Weighted Whole-Body Magnetic Resonance Imaging (DW-MRI) in patients who have undergone autologous stem cell transplantation (ASCT) after receiving first-line anti-CD38-based quadruplet induction therapy.Read full original descriptionShow less
Multicenter Observational Study for the Validation of the Predictive Role of Diffusion-Weighted Whole-body MRI (DW-MRI) Imaging Response According to MY-RADS Criteria (RAC Score) and Fat Fraction (rFF%) After Autologous Stem Cell Transplantation in Multiple Myeloma Patients Treated With First-Line Anti-CD38-Based Therapy (RAC-FAT Study)
This is a multicenter, observational, retrospective-prospective study designed to validate the predictive role of advanced imaging in patients with newly diagnosed multiple myeloma (NDMM). The main purpose of this study is to estimate the prevalence of radiological response categories (Response Assessment Category, RAC score) and evaluate the predictive value of relative Fat Fraction (rFF%) using Diffusion-Weighted Whole-Body Magnetic Resonance Imaging (DW-MRI) in patients who have undergone autologous stem cell transplantation (ASCT) after receiving first-line anti-CD38-based quadruplet induction therapy.
Inclusion: Newly diagnosed MM participants eligible for ASCT, treated with anti-CD38-based quadruplet induction therapy and ASCT, with post-ASCT/premaintenance DW-MRI available (in tandem ASCT, DW-MRI after second ASCT will be considered); Age ≥18 years; Participant must sign an informed consent form (ICF) that he or she understands the purpose of, and procedures required for the trial and is willing to participate in the trial.
Exclusion: Absence of post-ASCT/pre-maintenance DW-MRI.